Lauxera Capital Partners has successfully closed a €520 million fundraising round for its Lauxera Growth II fund, exceeding its initial target and demonstrating strong investor confidence.
The firm announced this significant milestone on May 19, highlighting that over 90% of previous investors from its 2021 fundraising returned with increased contributions. The primary objective of this fund is to support the growth of promising European healthtech and medtech companies, particularly by facilitating their expansion into the American market. Lauxera intends to invest in 12 to 15 established companies across sectors such as medical devices, digital health, and diagnostics.
Typical investments will range from €20 million to €50 million, with notable beneficiaries including German neurovascular device manufacturer Acandis and Swedish imaging firm Antaros Medical. The funding aims to accelerate product launches and ease entry into the U.S. market. Since its inception in 2021, Lauxera’s portfolio companies have generated over 400 jobs and launched numerous products, with significant success stories like OrganOx, which saw its revenue quintuple before being sold to Japan's Terumo Corp for approximately $1.5 billion.
The fundraising landscape for medtech and digital health has been robust, particularly in the U.S., where startups raised $9.9 billion in the first three quarters of 2025 alone. This trend includes larger investments, especially in companies leveraging artificial intelligence in healthcare, demonstrating a growing appetite for innovation in this sector. As Lauxera continues to strengthen its position, its impact on the European medtech landscape could be transformative, particularly in fostering collaborations and expansions into lucrative markets.